Tailored clotting treatment may cut bleeding after heart surgery
NCT ID NCT07425600
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aims to find the best dose of a clotting drug (fibrinogen) for patients after heart surgery using a heart-lung machine. Bleeding is a common complication, and current dosing is not personalized. Researchers will take blood samples from 150 adults to understand how fibrinogen levels change and how to give the minimum effective dose, potentially reducing bleeding and costs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fibrinogen concentrate
What this could lead to
If successful, this could lead to a personalized dosing strategy for fibrinogen after heart surgery, reducing bleeding and costs.
What could go wrong
This is an early observational study (not yet recruiting) with only 150 participants. It aims to understand variability, not to prove a new treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOFIBRINOGENEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Lille
Lille, 59000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de Saint-Etienne
Saint-Etienne, 42000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••